Your browser doesn't support javascript.
L-Arginine Enhances the Effects of Cardiac Rehabilitation on Physical Performance: New Insights for Managing Cardiovascular Patients During the COVID-19 Pandemic.
Mone, Pasquale; Izzo, Raffaele; Marazzi, Giuseppe; Manzi, Maria Virginia; Gallo, Paola; Campolongo, Giuseppe; Cacciotti, Luca; Tartaglia, Domenico; Caminiti, Giuseppe; Varzideh, Fahimeh; Santulli, Gaetano; Trimarco, Valentina.
  • Mone P; Departments of Medicine (Cardiology) and Molecular Pharmacology - Wilf Family Cardiovascular Research Institute, Fleischer Institute for Diabetes and Metabolism (FIDAM), Einstein Institute for Neuroimmunology and Inflammation, Einstein-Sinai Diabetes Research Center, Einstein Institute for Aging Res
  • Izzo R; Departments of Medicine (Cardiology) and Molecular Pharmacology - Wilf Family Cardiovascular Research Institute, Fleischer Institute for Diabetes and Metabolism (FIDAM), Einstein Institute for Neuroimmunology and Inflammation, Einstein-Sinai Diabetes Research Center, Einstein Institute for Aging Res
  • Marazzi G; Departments of Medicine (Cardiology) and Molecular Pharmacology - Wilf Family Cardiovascular Research Institute, Fleischer Institute for Diabetes and Metabolism (FIDAM), Einstein Institute for Neuroimmunology and Inflammation, Einstein-Sinai Diabetes Research Center, Einstein Institute for Aging Res
  • Manzi MV; Departments of Medicine (Cardiology) and Molecular Pharmacology - Wilf Family Cardiovascular Research Institute, Fleischer Institute for Diabetes and Metabolism (FIDAM), Einstein Institute for Neuroimmunology and Inflammation, Einstein-Sinai Diabetes Research Center, Einstein Institute for Aging Res
  • Gallo P; Departments of Medicine (Cardiology) and Molecular Pharmacology - Wilf Family Cardiovascular Research Institute, Fleischer Institute for Diabetes and Metabolism (FIDAM), Einstein Institute for Neuroimmunology and Inflammation, Einstein-Sinai Diabetes Research Center, Einstein Institute for Aging Res
  • Campolongo G; Departments of Medicine (Cardiology) and Molecular Pharmacology - Wilf Family Cardiovascular Research Institute, Fleischer Institute for Diabetes and Metabolism (FIDAM), Einstein Institute for Neuroimmunology and Inflammation, Einstein-Sinai Diabetes Research Center, Einstein Institute for Aging Res
  • Cacciotti L; Departments of Medicine (Cardiology) and Molecular Pharmacology - Wilf Family Cardiovascular Research Institute, Fleischer Institute for Diabetes and Metabolism (FIDAM), Einstein Institute for Neuroimmunology and Inflammation, Einstein-Sinai Diabetes Research Center, Einstein Institute for Aging Res
  • Tartaglia D; Departments of Medicine (Cardiology) and Molecular Pharmacology - Wilf Family Cardiovascular Research Institute, Fleischer Institute for Diabetes and Metabolism (FIDAM), Einstein Institute for Neuroimmunology and Inflammation, Einstein-Sinai Diabetes Research Center, Einstein Institute for Aging Res
  • Caminiti G; Departments of Medicine (Cardiology) and Molecular Pharmacology - Wilf Family Cardiovascular Research Institute, Fleischer Institute for Diabetes and Metabolism (FIDAM), Einstein Institute for Neuroimmunology and Inflammation, Einstein-Sinai Diabetes Research Center, Einstein Institute for Aging Res
  • Varzideh F; Departments of Medicine (Cardiology) and Molecular Pharmacology - Wilf Family Cardiovascular Research Institute, Fleischer Institute for Diabetes and Metabolism (FIDAM), Einstein Institute for Neuroimmunology and Inflammation, Einstein-Sinai Diabetes Research Center, Einstein Institute for Aging Res
  • Santulli G; Departments of Medicine (Cardiology) and Molecular Pharmacology - Wilf Family Cardiovascular Research Institute, Fleischer Institute for Diabetes and Metabolism (FIDAM), Einstein Institute for Neuroimmunology and Inflammation, Einstein-Sinai Diabetes Research Center, Einstein Institute for Aging Res
  • Trimarco V; Departments of Medicine (Cardiology) and Molecular Pharmacology - Wilf Family Cardiovascular Research Institute, Fleischer Institute for Diabetes and Metabolism (FIDAM), Einstein Institute for Neuroimmunology and Inflammation, Einstein-Sinai Diabetes Research Center, Einstein Institute for Aging Res
J Pharmacol Exp Ther ; 381(3): 197-203, 2022 06.
Article in English | MEDLINE | ID: covidwho-1765068
ABSTRACT
Cardiac rehabilitation (CR) following acute myocardial infarction (AMI) improves physical capacities and decreases hospitalizations and cardiovascular mortality. L-arginine is the substrate used by nitric oxide (NO) synthase to generate NO and it has been shown to exert its beneficial effects on endothelium driving vasodilatation, reducing inflammation, and ameliorating physical function. We hypothesized that L-arginine could enhance physical capacities in patients who underwent CR after AMI. We designed a study aimed to assess the effects of L-arginine administration on the physical capacity of patients who underwent coronary revascularization after AMI. The trial was carried out amid the COVID-19 pandemic. Patients were assigned, with a 21 ratio, to add to their standard therapy one bottle containing 1.66 g of L-arginine or one bottle of identical aspect apart from not containing L-arginine, twice a day orally for 3 weeks. Patients performed a 6-minute walking test (6MWT), and their Borg modified 0-10 rating of perceived exertion (BRPE) was assessed before starting and at the end of the treatment. Seventy-five patients receiving L-arginine, and 35 receiving placebo successfully completed the study. The 6MWT distance increased significantly in the L-arginine group compared with both baseline and placebo (P < 0.0001). Additionally, we observed a significant improvement in the BRPE in patients treated with L-arginine but not in the placebo group. Taken together, our data indicate that L-arginine potentiates the response to CR independently of age, sex, baseline functional capacity, and comorbid conditions. SIGNIFICANCE STATEMENT This study shows for the first time that oral supplementation of L-arginine potentiates the response to cardiac rehabilitation after myocardial infarction and cardiac revascularization. Indeed, we observed a significant improvement in two fundamental parameters, namely, the 6-minute walking test and the Borg modified 0-10 rating of perceived exertion. Strikingly, the beneficial effects of L-arginine were independent of age, sex, comorbid conditions, and baseline functional capacity.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cardiac Rehabilitation / COVID-19 / Myocardial Infarction Type of study: Experimental Studies / Randomized controlled trials Limits: Humans Language: English Journal: J Pharmacol Exp Ther Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Cardiac Rehabilitation / COVID-19 / Myocardial Infarction Type of study: Experimental Studies / Randomized controlled trials Limits: Humans Language: English Journal: J Pharmacol Exp Ther Year: 2022 Document Type: Article